Cargando…

Efficacy and Mechanism of Trimebutine Maleate Combined with Lactulose in the Treatment of Constipation-Predominant Irritable Bowel Syndrome in the Elderly

OBJECTIVE: Study on the efficacy and mechanism of trimebutine maleate combined with lactulose in the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in the elderly. METHODS: From March 2019 to March 2021, 102 elderly patients with IBS-C were randomly divided into the observati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yeping, Yang, Dujuan, Gu, Wenjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674410/ https://www.ncbi.nlm.nih.gov/pubmed/36406929 http://dx.doi.org/10.1155/2022/6125120

Ejemplares similares

Efficacy and safety of lactulose for the treatment of irritable bowel syndrome
por: Chen, Hong-Bin, et al.
Publicado: (2019)

Repositioning Trimebutine Maleate as a Cancer Treatment Targeting Ovarian Cancer Stem Cells
por: Lee, Heejin, et al.
Publicado: (2021)

Constipation-Predominant Irritable Bowel Syndrome Associated to Hyperprolactinemia
por: Seretis, C., et al.
Publicado: (2011)

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
por: Eswaran, Shanti, et al.
Publicado: (2014)

The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment
por: Karabulut, Gülcan S, et al.
Publicado: (2013)

The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis
por: Motawea, Amira, et al.
Publicado: (2022)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2020)

Efficacy and Safety of Acupoint Catgut Embedding for Diarrhea-Predominant Irritable Bowel Syndrome and Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Wu, Jing, et al.
Publicado: (2020)

Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation
por: Mourey, Florian, et al.
Publicado: (2022)

Gastroesophageal reflux disease, irritable bowel syndrome and functional dyspepsia as overlapping conditions: focus on effect of trimebutine
por: Kountouras, Jannis, et al.
Publicado: (2019)

White Matter Microstructural Similarity and Diversity of Functional Constipation and Constipation-predominant Irritable Bowel Syndrome
por: Nan, Jiaofen, et al.
Publicado: (2018)

Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial
por: Kountouras, Jannis, et al.
Publicado: (2020)

Comparison of Quality of Life and Psychiatric Symptoms Between Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Those With Constipation-Predominant Irritable Bowel Syndrome
por: BOUSABA, J., et al.
Publicado: (2023)

Functional Constipation and Constipation-Predominant Irritable Bowel Syndrome in the General Population: Data from the GECCO Study
por: Enck, Paul, et al.
Publicado: (2016)

Autonomic nervous system activity in constipation-predominant irritable bowel syndrome patients
por: Mazur, Marcel, et al.
Publicado: (2012)

Methane and Constipation-predominant Irritable Bowel Syndrome: Entwining Pillars of Emerging Neurogastroenterology
por: Bin Waqar, Syed Hamza, et al.
Publicado: (2019)

Prevalence of Subthreshold Depression Among Constipation-Predominant Irritable Bowel Syndrome Patients
por: Mokhtar, Norfilza Mohd, et al.
Publicado: (2020)

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)
por: Masuda, Hiroko, et al.
Publicado: (2023)

The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders
por: Kountouras, Jannis, et al.
Publicado: (2019)

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
por: Hamatani, Tatsuto, et al.
Publicado: (2020)

An evaluation of dietary adequacy among patients with constipation-predominant irritable bowel syndrome in Malaysia
por: Shafiee, Nor Hamizah, et al.
Publicado: (2022)

Efficacy of Newly Developed Kombucha-Based Specialized Food Product for Treatment of Constipation-Predominant Irritable Bowel Syndrome
por: Pilipenko, Vladimir, et al.
Publicado: (2022)

Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome
por: Lunsford, Tisha N, et al.
Publicado: (2010)

Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom
por: DiBonaventura, Marco daCosta, et al.
Publicado: (2012)

Comparison of Electroacupuncture and Moxibustion for Relieving Visceral Hypersensitivity in Rats with Constipation-Predominant Irritable Bowel Syndrome
por: Zhao, Ji-Meng, et al.
Publicado: (2016)

Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide
por: Chandar, Apoorva Krishna
Publicado: (2017)

Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report
por: Rey, Enrique, et al.
Publicado: (2017)

Comparison of fluoxetine and duloxetine hydrochloride therapeutic effects on patients with constipation-predominant irritable bowel syndrome
por: Jafari, Sattar, et al.
Publicado: (2022)

Internet survey on the actual situation of constipation in the Japanese population under 70 years old: focus on functional constipation and constipation-predominant irritable bowel syndrome
por: Kawamura, Yurika, et al.
Publicado: (2019)

The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties
por: Gobert, Alain P., et al.
Publicado: (2016)

Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome
por: Li, Dan-yan, et al.
Publicado: (2017)

Herbal Remedies for Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review of Randomized Controlled Trials
por: Chiarioni, Giuseppe, et al.
Publicado: (2023)

The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
por: Heidelbaugh, Joel J, et al.
Publicado: (2015)

Association between Symptoms of Irritable Bowel Syndrome and Methane and Hydrogen on Lactulose Breath Test
por: Lee, Kang Nyeong, et al.
Publicado: (2013)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

Differential mRNA Expression in Ileal Mucosal Biopsies of Patients With Diarrhea- or Constipation-Predominant Irritable Bowel Syndrome
por: Wang, Xiao Jing, et al.
Publicado: (2021)

Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms
por: Di Rosa, Claudia, et al.
Publicado: (2023)

Functional constipation masked as irritable bowel syndrome
por: Tosto, Monica, et al.
Publicado: (2020)

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China
por: Liu, Lan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lgs1im2ndd6df5jl6g8ai2ucn1